Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer

Positive

AI Analysis

Summary

Ailux appointed Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer to lead its AI-native biologics toward first-in-human trials, with clinical entry targeted for 2027. He will also establish a U.S. clinical and research site to complement operations in Shanghai and the U.K.

Outcome Details

Appointment of Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer; first-in-human trials targeted for 2027

Importance:4/10

Sentiment:

0.30

management_changeCMO_appointmentAI_drug_discoverybiologicspreclinical

Related Companies

$MDCE $TRAX

Read the original article

Published by PR Newswire Pharma on October 13, 2026 12:00 PM

Read Original